MedTrace Logo

Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy

NCT04920097 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2025-12-15

No results posted yet for this study

Summary

The proposed randomized control trial will evaluate auricular point acupressure (APA) on chemotherapy-induced neuropathy (CIN), rigorously considering point specificity and placebo effects by integrating self-report measures, psychophysical measures (QST), endogenous biomarkers (cytokines), and neuro-imaging to investigate APA's efficacy and underlying mechanism(s).

Conditions

  • Chemotherapy-induced Neuropathy

Interventions

OTHER

In-person training for seed placement and APA

In-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points.

OTHER

Virtual training for seed placement and APA

Self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement.

OTHER

Usual Care

Participants will continue with usual care from oncologist.

OTHER

Post-training zoom session for seed placement and APA coaching

Zoom session for seed placement and APA coaching, to occur after initial APA and seed placement training (initial training is either in person or guided by the smartphone app videos).

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Johns Hopkins University

    collaborator OTHER

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Jennifer Kawi, PhD, MSN, FNP-BC, CNE, FAAN · The University of Texas Health Science Center, Houston

  • Nada Lukkahatai, PHD, MSN, RN · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-08
Primary Completion
2025-05-30
Completion
2026-05-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920097 on ClinicalTrials.gov